SLC25A24 and malignant colon neoplasm: To explore the role of SLC25 in antineoplastic drug sensitivity, we utilized GDSC and found that SLC25A5 and SLC25A24, which are highly expressed in colon cancer and indicative of a relatively longer survival time, were associated with the ROCK inhibitor GSK269962A and foretinib sensitivity and tanespimycin, trametinib, and refametinib resistance (Fig. 3E), respectively.